-
Express | Janssen/Legendary Bio-CAR-T Therapy Completes Rolling Submission of FDA Biological Products License Application
Time of Update: 2021-04-19
CAR-T therapy ciltacabtagene autoleucel (cilta-cel) biological product license application (BLA) for the treatment of adult patients with relapsed/refractory multiple myeloma.
Janssen/Legendary's cilta-cel is expected to become the second approved cell therapy targeting BCMA this year, bringing more treatment options to patients with multiple myeloma.
-
Abecma has just been approved for listing, BMS/Bluebird issued a paper explaining the mechanism of BCMA CAR-T resistance
Time of Update: 2021-04-19
In March 2021, the CAR-T cell product Abecma (idecabtagene vicleucel; ide-cel) jointly developed by Bristol-Myers Squibb (BMS) and bluebird bio, with BCMA as the target, was approved by the US FDA to treat relapse or Drug-resistant multiple myeloma has become the fifth CAR-T product to be marketed in the world.
-
ENESTnd ten years and ENESTfreedom five years: Nilotinib long-term medication/discontinuation data update
Time of Update: 2021-04-19
ENESTnd ten-year data core conclusions The ENESTnd study enrolled 846 newly diagnosed CML-CP adult patients, and they were randomized 1:1:1 to nilotinib 300mg BID, nilotinib 400mg BID, and imatinib 400mg In the three treatment groups of QD, the primary endpoint is the 12-month major molecular remission (MMR) rate, and the 10-year long-term follow-up endpoints are designed, including the cumulative rate of molecular remission, long-term survival, and safety.
-
Interview with big coffee | Professor Yang Renchi: Clinical management practice of ITP patients with drug withdrawal
Time of Update: 2021-04-19
Yimaitong specially invited Professor Yang Renchi from the Institute of Hematology of the Chinese Academy of Medical Sciences to combine his own clinical diagnosis and treatment experience to discuss the early use and reduction of Eltrombopag.
-
Wonderful review｜CSCO Anti-Lymphoma Alliance Tour-Tianjin Station
Time of Update: 2021-04-19
Current status of clinical trials of bispecific antibodies in the treatment of lymphoma Speaker: Professor Zhu Jun from Peking University Cancer Hospital Chair: Professor Zhang Huilai from Tianjin Medical University Cancer Hospital Professor Zhu Jun said that bispecific antibodies are monoclonal antibodies that recognize two targets at the same time and play a combined role Drugs improve the selectivity and affinity of monoclonal antibodies, target effector cells to tumor cells, improve drug safety and effectiveness, and reduce development costs.
-
Children and adolescents with R/R ALL welcome new hope for cure, and long-term follow-up data reveals that CAR-T therapy bridges the survival of Allo-HSCT
Time of Update: 2021-04-19
Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) can improve the long-term time-free survival (EFS) rate of patients with R/R B-ALL remission after chemotherapy.
The median time for patients from receiving CAR-T cell infusion to Allo-HSCT was 54 days.
-
Professor Junning Cao: Research Progress of Extranodal NK/T Cell Lymphoma|The 4th China Conference on Individualized Lymphoma Treatment
Time of Update: 2021-04-19
At a median follow-up of 17 months, the 3-year progression-free survival (PFS) rate of NK/T-cell lymphoma patients reached 57.
-
Prof. Yi Shuhua: Diagnosis and Treatment Progress of Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma|The 4th China Conference on Chronic Lymphocytic Leukemia
Time of Update: 2021-04-18
Diagnosis and Difficulties of LPL/WM Professor Yi Shuhua introduced that the diagnostic criteria of WM mainly include the following: first, the detection of monoclonal IgM in the serum (regardless of the quantity); second, the plasma cell-like or the like in the bone marrow The small lymphocytes differentiated by plasma cells are invaded by the trabecular space (regardless of the number); third, their immunophenotypes are: slgM+, CD5-, CD10-, CD11c-, CD19+, CD20+, CD22+, CD23-, CD25+, CD27+, FMC7+, CD79a+, CD103-, CD38/138+.
-
NEJM has two heavyweights!
Time of Update: 2021-04-18
, The researchers obtained serum from 9 patients to study platelet activation antibodies against platelet factor 4 (PF4)-heparin.
Figure 1B shows the platelet activation results of serum samples from 24 patients with clinically suspected vaccine-induced immune thrombotic thrombocytopenia.
-
Express | Let the "no medicine to cure" patients get complete relief!
Time of Update: 2021-04-18
However, after participating in a clinical trial and receiving an innovative immunotherapy treatment called "natural killer" (NK), the two patients achieved complete remission.
"Reference: [1] Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13.
-
Nature Sub-Journal: Breaking with traditional cognition, Xu Jian's team discovered the tumor suppressor effect of jumping genes
Time of Update: 2021-04-18
This study unexpectedly found that retrotransposon LINE-1 with complete transposition activity has a tumor suppressor function in the development of myeloid leukemia, and clarified that LINE-1 activates DNA damage checkpoints through retrotransposition and affects genome stability.
-
Blood | Significant progress!
Time of Update: 2021-04-18
On March 24, 2021, Zhang Haojian’s team from Wuhan University published an online research paper entitled "YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner" in Blood (IF=17.
-
Umbralisib is expected to become a safe and effective treatment for R/R iNHL patients
Time of Update: 2021-04-18
Fowler and others conducted a phase IIb clinical study to evaluate the PI3Kδ/CK-1ε dual inhibitor Umbralisib in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma (R/R iNHL) Efficacy and safety.
-
Dexamethasone combined with oseltamivir can effectively improve the efficacy of newly diagnosed ITP patients: the latest research results of Professor Ming Hou’s team
Time of Update: 2021-04-18
Therefore, the team of Professor Ming Hou launched a multi-center, open-label, randomized phase II clinical trial comparing dexamethasone combined with oseltamivir and dexamethasone monotherapy in the treatment of adult newly diagnosed ITP.
-
Glofitamab is expected to break through the curative effect bottleneck of R/R B-NHL
Time of Update: 2021-04-18
The primary research endpoints are the safety of the patient, the pharmacokinetics of Glofitamab and the maximum tolerated dose; the secondary research endpoints include the patient’s total response rate (ORR), duration of response (DOR), duration of complete response (DOCR) and Progression-free survival (PFS), etc.
-
Professor Liu Wei: In the era of CAR-T treatment, the status of transplantation in DLBCL｜CSCO Anti-Lymphoma Alliance Tour
Time of Update: 2021-04-18
The results showed that the 4-year progression-free survival (PFS) rate of PET-positive patients before transplantation was 32%.
These three studies compare the efficacy of salvage chemotherapy + ASCT and direct CAR-T in second-line treatment.
-
Professor Xu Bing: Diagnosis and Treatment of FL|The 4th China Chronic Lymphocytic Leukemia Conference
Time of Update: 2021-04-18
A study in The Lancet showed that Tazemetostat (EZH2 inhibitor) as a single agent can effectively treat FL (1-3b) patients who relapse after multi-line treatment.
Therefore, Professor Xu Bing said that although the use of BTK inhibitors to treat patients with relapsed FL has a certain effect, it is relatively limited.
-
The dilemma of CD30+ lymphoma, how can targeted drugs break the situation?
Time of Update: 2021-04-18
Among them, the antibody-conjugated drug (ADC) Vebutuximab (BV) that targets CD30 has been long-awaited, and was finally approved by the China National Medical Products Administration for the treatment of CD30-positive patients in May 2020.
-
IDH1/2 inhibitor Ivosidenib/Enasidenib combined with intensive chemotherapy is well tolerated in newly treated AML patients
Time of Update: 2021-04-18
Research methods The study included newly-treated AML patients aged ≥18 years, ECOG score 0-2, and IDH1/2 mutations, who received 500mg/day Ivosidenib/Enasidenib combined with cytarabine (200mg/m2/day, total 7 Day) and daunorubicin (60mg/m2/day for 3 days) induction therapy.
-
NEJM: Sutimlimab is effective in treating cold agglutinin disease
Time of Update: 2021-04-17
Sutimlimab can rapidly improve the symptoms of hemolysis in patients with cold agglutinin disease by selectively inhibiting the upstream target of the classical complement pathway , increase hemoglobin levels and reduce fatigue.
